<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01734850</url>
  </required_header>
  <id_info>
    <org_study_id>CAL-USA-11</org_study_id>
    <nct_id>NCT01734850</nct_id>
  </id_info>
  <brief_title>Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection</brief_title>
  <official_title>An Adaptive Phase I/II Study of the Safety of CD4+ T Lymphocytes and CD34+ Hematopoietic Stem/Progenitor Cells Transduced With LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct, With and Without Conditioning With Busulfan in HIV-1 Infected Adults Previously Exposed to ART</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calimmune, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calimmune, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an early phase research study looking at whether an experimental gene transfer,&#xD;
      LVsh5/C46 (also known as Cal-1), is safe and if it can protect the immune system from the&#xD;
      effects of HIV without the use of antiretroviral drugs.&#xD;
&#xD;
      Cal-1 is an experimental gene transfer agent designed to inhibit HIV infection through 2&#xD;
      active parts:&#xD;
&#xD;
        1. Removing a protein named CCR5 from bone marrow and white blood cells&#xD;
&#xD;
        2. Producing a protein named C46 on bone marrow and white blood cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is estimated that 33 million individuals are currently infected with HIV. HIV/AIDS is a&#xD;
      disease that impairs immune function, primarily by decreasing CD4+ T lymphocytes. The&#xD;
      progression can be contained by daily dosing with antiretroviral therapy (ART) but there are&#xD;
      side effects that can be treatment limiting, and the development of HIV drug resistance can&#xD;
      force the physician to modify the ART regimen. There are no effective vaccines currently&#xD;
      available for HIV.&#xD;
&#xD;
      LVsh5/C46 (also known as Cal-1) is a dual therapeutic, self-inactivating lentiviral vector&#xD;
      that encodes for both a short hairpin RNA against the HIV-1 co-receptor CCR5 (sh5) and a&#xD;
      HIV-1 fusion inhibitor, C46 and inhibits two processes required for HIV-1 infection:&#xD;
&#xD;
        1. Binding of the virus to the cellular CCR5 co-receptor and&#xD;
&#xD;
        2. Fusion of the virus with the host cell&#xD;
&#xD;
      The rationale is that Cal-1 introduced into hematopoietic progenitor/stem cells (HSPC) and&#xD;
      mature CD4+ T lymphocytes will protect these cells and their progeny cells from HIV-1&#xD;
      infection and its pathogenic sequelae. This may provide a continuous means of controlling&#xD;
      HIV-1 after a single or infrequent dose(s), thereby decreasing or delaying (partially or&#xD;
      completely) the need for antiretroviral drug therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2013</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Severe and Life-threatening Adverse Events (AEs)</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Severe or Life-threatening AEs Related to CSL202</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With the Presence of Replication-competent Retrovirus</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Predominant Integration Site Analysis</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Vector Integration Site Analysis performed only when Cal-1 Marking is &gt;= 1%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Cell Dose for CD4+ Cells (Ttn)</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Cell Dose for CD34+ Cells (HSPCtn)</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Transduction Efficiency of CD4+ Cells (Ttn) and CD34+ Cells (HSPCtn) of Final Cell Product</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Area Under the Curve (AUC) for Busulfan</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Cohort 3: Total AUC = first dose AUC value + second dose AUC value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Cal-1 Marking in Peripheral Blood</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cal-1 Marking in Gut-associated Lymphoid Tissue (GALT) (10-15 cm)</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Samples were collected via endoscopic biopsy from the sigmoid colon: 10-15 cm from the anal margin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cal-1 Marking in GALT (25-35 cm)</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Samples were collected via endoscopic biopsy from the sigmoid colon: 25-35 cm from the anal margin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cal-1 Marking in Bone Marrow</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cal-1 C46 Expression in Peripheral Blood</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>C46 relative expression will be analyzed by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) and normalized to the expression of β2-microglobulin (β2M) mRNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cal-1 sh5 Expression in Peripheral Blood</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>sh5 relative expression will be analyzed by RT-qPCR and normalized to the expression of RNU38B microRNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV Viral Load at Baseline Screening and Week 48 or at Anti-retroviral Therapy (ART) Re-commencement</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ Count at Baseline Screening and Week 48 or at ART Re-commencement</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HIV-1 Tropism Shift</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Shift from R5 to X4 or dual/mixed tropism</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>No busulfan pre-conditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes without busulfan preconditioning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 x 4mg/kg busulfan preconditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes, with single 4mg/kg busulfan dose administered as pre-conditioning for transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 x 4mg/kg busulfan pre-conditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes, with two 4mg/kg busulfan doses administered as pre-conditioning for transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Intravenous busulfan</description>
    <arm_group_label>1 x 4mg/kg busulfan preconditioning</arm_group_label>
    <arm_group_label>2 x 4mg/kg busulfan pre-conditioning</arm_group_label>
    <other_name>Busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cal-1 modified HSPC</intervention_name>
    <description>Hematopoietic progenitor/stem cells (HSPC) modified with LVsh5/C46 (Cal-1)</description>
    <arm_group_label>1 x 4mg/kg busulfan preconditioning</arm_group_label>
    <arm_group_label>2 x 4mg/kg busulfan pre-conditioning</arm_group_label>
    <arm_group_label>No busulfan pre-conditioning</arm_group_label>
    <other_name>LVsh5/C46 modified HSPC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cal-1 modified CD4+ T lymphocytes</intervention_name>
    <description>CD4+ T lymphocytes modified with LVsh5/C46 (Cal-1)</description>
    <arm_group_label>1 x 4mg/kg busulfan preconditioning</arm_group_label>
    <arm_group_label>2 x 4mg/kg busulfan pre-conditioning</arm_group_label>
    <arm_group_label>No busulfan pre-conditioning</arm_group_label>
    <other_name>LVsh5/C46 modified CD4+ T lymphocytes</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prior to any study-related procedures, signed informed consent indicating that they&#xD;
             understand the purpose, risks and procedures required for the study and are willing to&#xD;
             participate in the study&#xD;
&#xD;
          -  Individuals aged 18 to 65 years of age (inclusive) at time of consent&#xD;
&#xD;
          -  Documented HIV-1 infection ≥ 6 months prior to Screening 1&#xD;
&#xD;
          -  Previous treatment with antiretroviral agents that had a demonstrated suppressive&#xD;
             effect (defined as plasma HIV RNA ≤ 50 copies/ml)&#xD;
&#xD;
          -  A documented viable ART regimen option, as determined by the Investigator, taking into&#xD;
             account prior ART experience and HIV geno/phenotyping analyses&#xD;
&#xD;
          -  Not taking antiretroviral therapy for ≥ 6 weeks prior to Screening 1, for one or more&#xD;
             of the following reasons:&#xD;
&#xD;
             i) Concerns over short-term or long-term toxicities associated with antiretroviral&#xD;
             agents, or ii) Treatment fatigue from the daily regimen of life-long therapy&#xD;
&#xD;
          -  Plasma HIV-1 viral RNA ≥ 5,000 copies/mL and ≤ 100,000 copies/ml at Screening 1 and&#xD;
             Screening 2&#xD;
&#xD;
          -  CD4+ T lymphocyte count ≥ 500 cells/µl at Screening 1 and Screening 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal hematology at Screening 1: Absolute neutrophil count (ANC) &lt; 1.5 x 109/L,&#xD;
             Platelet count &lt; 100 x 109/L, Hemoglobin &lt; 10 g/dL&#xD;
&#xD;
          -  Abnormal biochemistry at Screening 1: Alanine aminotransferase (ALT) &gt; 2.5 x Upper&#xD;
             Limit of Normal (ULN), Total bilirubin &gt; 1.5 x ULN, Serum creatinine &gt; 1.5 x ULN&#xD;
&#xD;
          -  Detection of any CXCR4-tropic HIV-1 at Screening 1&#xD;
&#xD;
          -  Evidence of co-infection with hepatitis B virus, hepatitis C virus, West Nile Virus,&#xD;
             or HTLV-1 as detected at Screening 2&#xD;
&#xD;
          -  Evidence of active TB infection determined by positive QuantiFERON®-TB Gold/IGRA test&#xD;
             result and clinical confirmation at Screening 2&#xD;
&#xD;
          -  ART or other antiretroviral therapy within 6 weeks of Screening 1 or any time during&#xD;
             the pre-infusion period&#xD;
&#xD;
          -  Documented history of CD4+ T lymphocyte count &lt; 250 cells/µl&#xD;
&#xD;
          -  Any previous or current AIDS-defining illnesses (CDC Category C), including&#xD;
             AIDS-related dementia, with the exception of Kaposi's sarcoma confined to the skin&#xD;
&#xD;
          -  History of malignancy or systemic chemotherapy within the last 5 years (i.e., subjects&#xD;
             with prior malignancy must be disease-free for 5 years), except curatively-treated&#xD;
             basal cell carcinoma, cutaneous squamous cell carcinoma, or cervical or anal&#xD;
             intra-epithelial neoplasia&#xD;
&#xD;
          -  History of steroid-dependent asthma in the past 5 years&#xD;
&#xD;
          -  History of seizure&#xD;
&#xD;
          -  Any clinical history of hematologic diseases including leukemia, myelodysplasia,&#xD;
             myeloproliferative disease, thromboembolic disease, sickle cell disorder,&#xD;
             thrombocytopenia or leukopenia&#xD;
&#xD;
          -  Class II-IV heart failure, according to the New York Heart Association classification&#xD;
&#xD;
          -  Inadequate venous access for apheresis, as assessed at Screening 1&#xD;
&#xD;
          -  Current or planned systemic immunosuppressive or immunomodulatory medication&#xD;
&#xD;
          -  Taking warfarin, aspirin or any medication that is likely to affect platelet function&#xD;
             or other aspects of blood coagulation, and unable to safely cease this medication for&#xD;
             a period of 1 week prior, during, and 1 week after administration of G-CSF (a total&#xD;
             period of 19 days)&#xD;
&#xD;
          -  Participation in any study involving any investigational drug or medical device within&#xD;
             30 days prior to Screening 1&#xD;
&#xD;
          -  Receipt of a vaccine for HIV-1 or any gene transfer product at any time&#xD;
&#xD;
          -  Prior treatment with recombinant G-CSF or busulfan or other stem-cell mobilizing or&#xD;
             modulating agent within the previous 12 months&#xD;
&#xD;
          -  Known hypersensitivity to busulfan, G-CSF (Neupogen™) or E. coli-derived proteins&#xD;
&#xD;
          -  Subjects who will not accept transfusions of blood products&#xD;
&#xD;
          -  Pregnant or breast-feeding at any time between Screening 1 and Baseline (infusion)&#xD;
&#xD;
          -  History of alcohol or drug abuse within the 12 months prior to Screening 1&#xD;
&#xD;
          -  Inability to understand and provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Mitsuyasu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA CARE Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 19, 2012</study_first_submitted>
  <study_first_submitted_qc>November 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2012</study_first_posted>
  <results_first_submitted>June 25, 2020</results_first_submitted>
  <results_first_submitted_qc>July 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 6, 2020</results_first_posted>
  <disposition_first_submitted>September 17, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>September 17, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 24, 2018</disposition_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 8, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT01734850/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT01734850/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1 (CSL202 With No Busulfan)</title>
          <description>Cal-1 modified Hematopoietic stem/progenitor cells (HSPC) and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2 (CSL202 With 1 Busulfan Dose)</title>
          <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3 (CSL202 With 2 Busulfan Doses)</title>
          <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC) administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Continued to Week 48 but recommenced ART</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not infused due to manufacturing failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1 (CSL202 With No Busulfan)</title>
          <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2 (CSL202 With 1 Busulfan Dose)</title>
          <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3 (CSL202 With 2 Busulfan Doses)</title>
          <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC)administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.0" spread="11.7"/>
                    <measurement group_id="B2" value="48.5" spread="12.8"/>
                    <measurement group_id="B3" value="46.8" spread="3.1"/>
                    <measurement group_id="B4" value="46.2" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Severe and Life-threatening Adverse Events (AEs)</title>
        <time_frame>Up to 48 weeks</time_frame>
        <population>Safety Population (SP): The safety population includes all enrolled subjects signing informed consent who started the interventional phase of the trial (i.e. CD4+ Apheresis and discontinued subjects who re-commenced ART)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (CSL202 With No Busulfan)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (CSL202 With 1 Busulfan Dose)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 (CSL202 With 2 Busulfan Doses)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC) administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe and Life-threatening Adverse Events (AEs)</title>
          <population>Safety Population (SP): The safety population includes all enrolled subjects signing informed consent who started the interventional phase of the trial (i.e. CD4+ Apheresis and discontinued subjects who re-commenced ART)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life-threatening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Severe or Life-threatening AEs Related to CSL202</title>
        <time_frame>Up to 48 weeks</time_frame>
        <population>SP</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (CSL202 With No Busulfan)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (CSL202 With 1 Busulfan Dose)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 (CSL202 With 2 Busulfan Doses)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC)administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe or Life-threatening AEs Related to CSL202</title>
          <population>SP</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With the Presence of Replication-competent Retrovirus</title>
        <time_frame>Up to 48 weeks</time_frame>
        <population>SP</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (CSL202 With No Busulfan)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (CSL202 With 1 Busulfan Dose)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 (CSL202 With 2 Busulfan Doses)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC)administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Presence of Replication-competent Retrovirus</title>
          <population>SP</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Predominant Integration Site Analysis</title>
        <description>Vector Integration Site Analysis performed only when Cal-1 Marking is &gt;= 1%.</description>
        <time_frame>Up to 48 weeks</time_frame>
        <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (CSL202 With No Busulfan)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (CSL202 With 1 Busulfan Dose)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 (CSL202 With 2 Busulfan Doses)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC)administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Predominant Integration Site Analysis</title>
          <description>Vector Integration Site Analysis performed only when Cal-1 Marking is &gt;= 1%.</description>
          <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not done because Cal-1 Marking was &lt;1% at the corresponding time point required</measurement>
                    <measurement group_id="O2" value="NA">Not done because Cal-1 Marking was &lt;1% at the corresponding time point required</measurement>
                    <measurement group_id="O3" value="NA">Not done because Cal-1 Marking was &lt;1% at the corresponding time point required</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Cell Dose for CD4+ Cells (Ttn)</title>
        <time_frame>Up to 48 weeks</time_frame>
        <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (CSL202 With No Busulfan)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (CSL202 With 1 Busulfan Dose)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 (CSL202 With 2 Busulfan Doses)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC)administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cell Dose for CD4+ Cells (Ttn)</title>
          <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
          <units>Number (10^8 cells)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.940" lower_limit="14.61" upper_limit="20.62"/>
                    <measurement group_id="O2" value="81.855" lower_limit="38.94" upper_limit="138.68"/>
                    <measurement group_id="O3" value="49.553" lower_limit="20.70" upper_limit="79.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Cell Dose for CD34+ Cells (HSPCtn)</title>
        <time_frame>Up to 48 weeks</time_frame>
        <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (CSL202 With No Busulfan)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (CSL202 With 1 Busulfan Dose)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 (CSL202 With 2 Busulfan Doses)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC)administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cell Dose for CD34+ Cells (HSPCtn)</title>
          <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
          <units>Number (10^6 cells/kg body weight)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="0.35" upper_limit="5.0"/>
                    <measurement group_id="O2" value="2.4" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="10.6" lower_limit="7.4" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Transduction Efficiency of CD4+ Cells (Ttn) and CD34+ Cells (HSPCtn) of Final Cell Product</title>
        <time_frame>Up to 48 weeks</time_frame>
        <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (CSL202 With No Busulfan)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (CSL202 With 1 Busulfan Dose)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 (CSL202 With 2 Busulfan Doses)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC)administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Transduction Efficiency of CD4+ Cells (Ttn) and CD34+ Cells (HSPCtn) of Final Cell Product</title>
          <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
          <units>Percent transduction efficiency</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4+ Cells (Ttn)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0" lower_limit="21.0" upper_limit="60.0"/>
                    <measurement group_id="O2" value="29.2" lower_limit="13.0" upper_limit="39.0"/>
                    <measurement group_id="O3" value="66.8" lower_limit="39.0" upper_limit="84.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD34+ Cells (HSPCtn)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" lower_limit="51.0" upper_limit="77.0"/>
                    <measurement group_id="O2" value="26.3" lower_limit="12.0" upper_limit="53.0"/>
                    <measurement group_id="O3" value="31.3" lower_limit="21.0" upper_limit="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Area Under the Curve (AUC) for Busulfan</title>
        <description>Cohort 3: Total AUC = first dose AUC value + second dose AUC value</description>
        <time_frame>Up to 48 weeks</time_frame>
        <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2 (CSL202 With 1 Busulfan Dose)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
          <group group_id="O2">
            <title>Cohort 3 (CSL202 With 2 Busulfan Doses)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC) administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
        </group_list>
        <measure>
          <title>Total Area Under the Curve (AUC) for Busulfan</title>
          <description>Cohort 3: Total AUC = first dose AUC value + second dose AUC value</description>
          <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
          <units>micromolar*min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6521.5" lower_limit="5863" upper_limit="7259"/>
                    <measurement group_id="O2" value="8296.8" lower_limit="7893" upper_limit="8601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Cal-1 Marking in Peripheral Blood</title>
        <time_frame>Up to 48 weeks</time_frame>
        <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (CSL202 With No Busulfan)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (CSL202 With 1 Busulfan Dose)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 (CSL202 With 2 Busulfan Doses)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC)administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Cal-1 Marking in Peripheral Blood</title>
          <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
          <units>percent Cal-1 marking</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peak marking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3500" lower_limit="0.0000" upper_limit="1.1600"/>
                    <measurement group_id="O2" value="0.7650" lower_limit="0.6100" upper_limit="0.8900"/>
                    <measurement group_id="O3" value="3.1200" lower_limit="0.1800" upper_limit="7.4600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000" lower_limit="0.0000" upper_limit="0.0000"/>
                    <measurement group_id="O2" value="0.1275" lower_limit="0.0000" upper_limit="0.3800"/>
                    <measurement group_id="O3" value="0.1275" lower_limit="0.0000" upper_limit="0.4900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cal-1 Marking in Gut-associated Lymphoid Tissue (GALT) (10-15 cm)</title>
        <description>Samples were collected via endoscopic biopsy from the sigmoid colon: 10-15 cm from the anal margin</description>
        <time_frame>Up to 48 weeks</time_frame>
        <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (CSL202 With No Busulfan)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (CSL202 With 1 Busulfan Dose)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 (CSL202 With 2 Busulfan Doses)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC)administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
        </group_list>
        <measure>
          <title>Cal-1 Marking in Gut-associated Lymphoid Tissue (GALT) (10-15 cm)</title>
          <description>Samples were collected via endoscopic biopsy from the sigmoid colon: 10-15 cm from the anal margin</description>
          <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
          <units>copies/cell</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peak marking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8121" lower_limit="0.0" upper_limit="2.7054"/>
                    <measurement group_id="O2" value="0.0007" lower_limit="0.0" upper_limit="0.0019"/>
                    <measurement group_id="O3" value="0.0022" lower_limit="0.0006" upper_limit="0.0060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8121" lower_limit="0.0" upper_limit="2.7054"/>
                    <measurement group_id="O2" value="0.0004" lower_limit="0.0" upper_limit="0.0010"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0" upper_limit="0.0004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cal-1 Marking in GALT (25-35 cm)</title>
        <description>Samples were collected via endoscopic biopsy from the sigmoid colon: 25-35 cm from the anal margin</description>
        <time_frame>Up to 48 weeks</time_frame>
        <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (CSL202 With No Busulfan)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (CSL202 With 1 Busulfan Dose)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 (CSL202 With 2 Busulfan Doses)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC)administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
        </group_list>
        <measure>
          <title>Cal-1 Marking in GALT (25-35 cm)</title>
          <description>Samples were collected via endoscopic biopsy from the sigmoid colon: 25-35 cm from the anal margin</description>
          <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
          <units>copies/cell</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peak marking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0255" lower_limit="0.0" upper_limit="0.0677"/>
                    <measurement group_id="O2" value="0.0003" lower_limit="0.0" upper_limit="0.0011"/>
                    <measurement group_id="O3" value="0.0068" lower_limit="0.0020" upper_limit="0.0186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0255" lower_limit="0.0" upper_limit="0.0677"/>
                    <measurement group_id="O2" value="0.0003" lower_limit="0.0" upper_limit="0.0011"/>
                    <measurement group_id="O3" value="0.0055" lower_limit="0.0" upper_limit="0.0186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cal-1 Marking in Bone Marrow</title>
        <time_frame>Up to 48 weeks</time_frame>
        <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (CSL202 With No Busulfan)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (CSL202 With 1 Busulfan Dose)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 (CSL202 With 2 Busulfan Doses)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC)administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
        </group_list>
        <measure>
          <title>Cal-1 Marking in Bone Marrow</title>
          <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
          <units>copies/cell</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peak marking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0007" lower_limit="0.0" upper_limit="0.0026"/>
                    <measurement group_id="O2" value="0.0539" lower_limit="0.0005" upper_limit="0.2027"/>
                    <measurement group_id="O3" value="0.0021" lower_limit="0.0009" upper_limit="0.0030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0007" lower_limit="0.0" upper_limit="0.0026"/>
                    <measurement group_id="O2" value="0.0015" lower_limit="0.0005" upper_limit="0.0044"/>
                    <measurement group_id="O3" value="0.0009" lower_limit="0.0003" upper_limit="0.0025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cal-1 C46 Expression in Peripheral Blood</title>
        <description>C46 relative expression will be analyzed by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) and normalized to the expression of β2-microglobulin (β2M) mRNA</description>
        <time_frame>Up to 48 weeks</time_frame>
        <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (CSL202 With No Busulfan)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (CSL202 With 1 Busulfan Dose)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 (CSL202 With 2 Busulfan Doses)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC)administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
        </group_list>
        <measure>
          <title>Cal-1 C46 Expression in Peripheral Blood</title>
          <description>C46 relative expression will be analyzed by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) and normalized to the expression of β2-microglobulin (β2M) mRNA</description>
          <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
          <units>units of relative expression</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peak marking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000" lower_limit="0.0000" upper_limit="0.0000"/>
                    <measurement group_id="O2" value="1.0496" lower_limit="0.0000" upper_limit="2.9977"/>
                    <measurement group_id="O3" value="2.1701" lower_limit="0.0000" upper_limit="6.4800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000" lower_limit="0.0000" upper_limit="0.0000"/>
                    <measurement group_id="O2" value="0.0000" lower_limit="0.0000" upper_limit="0.0000"/>
                    <measurement group_id="O3" value="0.0000" lower_limit="0.0000" upper_limit="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cal-1 sh5 Expression in Peripheral Blood</title>
        <description>sh5 relative expression will be analyzed by RT-qPCR and normalized to the expression of RNU38B microRNA</description>
        <time_frame>Up to 48 weeks</time_frame>
        <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (CSL202 With No Busulfan)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (CSL202 With 1 Busulfan Dose)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 (CSL202 With 2 Busulfan Doses)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC)administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
        </group_list>
        <measure>
          <title>Cal-1 sh5 Expression in Peripheral Blood</title>
          <description>sh5 relative expression will be analyzed by RT-qPCR and normalized to the expression of RNU38B microRNA</description>
          <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
          <units>units of relative expression</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peak marking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000" lower_limit="0.0000" upper_limit="0.0000"/>
                    <measurement group_id="O2" value="0.2027" lower_limit="0.0000" upper_limit="0.6489"/>
                    <measurement group_id="O3" value="1.6933" lower_limit="0.1930" upper_limit="4.6736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000" lower_limit="0.0000" upper_limit="0.0000"/>
                    <measurement group_id="O2" value="0.0000" lower_limit="0.0000" upper_limit="0.0000"/>
                    <measurement group_id="O3" value="0.0000" lower_limit="0.0000" upper_limit="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV Viral Load at Baseline Screening and Week 48 or at Anti-retroviral Therapy (ART) Re-commencement</title>
        <time_frame>Up to 48 weeks</time_frame>
        <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (CSL202 With No Busulfan)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (CSL202 With 1 Busulfan Dose)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 (CSL202 With 2 Busulfan Doses)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC)administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Viral Load at Baseline Screening and Week 48 or at Anti-retroviral Therapy (ART) Re-commencement</title>
          <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
          <units>Log10 (copies/mL)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.59" lower_limit="4.06" upper_limit="4.87"/>
                    <measurement group_id="O2" value="4.51" lower_limit="3.98" upper_limit="4.82"/>
                    <measurement group_id="O3" value="4.28" lower_limit="3.45" upper_limit="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 or at ART re-commencement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.56" lower_limit="4.00" upper_limit="4.93"/>
                    <measurement group_id="O2" value="4.70" lower_limit="3.88" upper_limit="4.96"/>
                    <measurement group_id="O3" value="4.61" lower_limit="4.20" upper_limit="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4+ Count at Baseline Screening and Week 48 or at ART Re-commencement</title>
        <time_frame>Up to 48 weeks</time_frame>
        <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (CSL202 With No Busulfan)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (CSL202 With 1 Busulfan Dose)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 (CSL202 With 2 Busulfan Doses)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC)administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+ Count at Baseline Screening and Week 48 or at ART Re-commencement</title>
          <population>SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn)</population>
          <units>CD4+ cells/cubic mm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="680.75" lower_limit="522.5" upper_limit="809.5"/>
                    <measurement group_id="O2" value="575.13" lower_limit="537.0" upper_limit="677.5"/>
                    <measurement group_id="O3" value="668.63" lower_limit="529.0" upper_limit="878.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 or at ART re-commencement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="553.3" lower_limit="450" upper_limit="759"/>
                    <measurement group_id="O2" value="383.5" lower_limit="274" upper_limit="549"/>
                    <measurement group_id="O3" value="245.5" lower_limit="152" upper_limit="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HIV-1 Tropism Shift</title>
        <description>Shift from R5 to X4 or dual/mixed tropism</description>
        <time_frame>Up to 48 weeks</time_frame>
        <population>SP</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 (CSL202 With No Busulfan)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 (CSL202 With 1 Busulfan Dose)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3 (CSL202 With 2 Busulfan Doses)</title>
            <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC)administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV-1 Tropism Shift</title>
          <description>Shift from R5 to X4 or dual/mixed tropism</description>
          <population>SP</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 48 weeks per participant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1 (CSL202 With No Busulfan)</title>
          <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2 (CSL202 With 1 Busulfan Dose)</title>
          <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3 (CSL202 With 2 Busulfan Doses)</title>
          <description>Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC) administered as pre-conditioning for transplant&#xD;
Busulfan: Intravenous busulfan</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="38" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E3" events="21" subjects_affected="5" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="19" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E3" events="40" subjects_affected="4" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="18" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>ear congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Faeces soft</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Tongue discolouration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Night Sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Secondary syphilis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>CD4 lymphocytes decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Somnambulism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Haematospermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Tonsillar disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin odour abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash vesicular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Eosinophilic pustular folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Registration Coordinator</name_or_title>
      <organization>CSL Behring</organization>
      <phone>484-878-4000</phone>
      <email>clinicaltrials@cslbehring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

